<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2020</study_start_year><condition>OGIB, Small bowel stenosis, small bowel tumor, inflammatory bowel disease</condition><condition>OGIB, small intestine, inflammatory bowel disease, small intestine endoscope</condition><disease>Ogib, Small Intestine, Inflammatory Bowel Disease, Small Intestine Endoscope</disease><disease>Ogib, Small Bowel Stenosis, Small Bowel Tumor, Inflammatory Bowel Disease</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2614340</full_dataset_link><study_start_month>4</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Randomized controlled trial examining the usefulness and safety of midazolam continuous intravenous infusion and pethidine hydrochloride in small intestine endoscope</name><description>Interventions: Midazolam single intravenous + pethidine hydrochloride combination
Midazolam continuous intravenous infusion + pethidine hydrochloride combination;Midazolam single intravenous, Midazolam continuous intravenous infusion
Primary outcome(s): Proper sedation rate
Study Design: randomized controlled trial, double blind, active control, parallel assignment, treatment purpose</description><dates><creation>2020-04-15</creation></dates><accession>2614340</accession><cross_references><Japan Primary Registries Network>JPRN-jRCTs031200018</Japan Primary Registries Network></cross_references></HashMap>